US OptionsDetailed Quotes

ANNX240816P8000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Jul 19 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    $Annexon(ANNX.US)$
    Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
    Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atroph...
    $Annexon(ANNX.US)$ Did anyone remember to be watching for this? I told Y’all on the 18th to be looking! Hehehe
    $Annexon(ANNX.US)$ Reuters· 5 mins ago
    Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
    $Annexon(ANNX.US)$
    Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
    Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
    Significant improvements were noted in primary and mult...
    $Annexon(ANNX.US)$ Annexon to Present Significant Phase 3 Results of ANX005 in Guillain-Barré Syndrome at PNS Annual Meeting; Potential to Be First Targeted Therapy for GBS! June 22-25,  2024
Read more